Federico Pulido

6PUBLICATIONS
21CO-AUTHORS
Applied linguistics and educational linguisticsGene and molecular therapyMedical virologyDiscourse and pragmaticsDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 21, 2026
Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL).

|Aug 14, 2026
VOGUE: Noninferior Efficacy of Dolutegravir/Lamivudine Versus Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults With HIV-1 Naive to Treatment.

|Nov 30, 2022
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance.

Rosa De Miguel Buckley, David Rial-Crestelo, Rocío Montejano

|Nov 21, 2022
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.

Alfonso Cabello-Ubeda, Juan Carlos López Bernardo de Quirós, Luz Martín Carbonero

|Mar 14, 2020
Cabotegravir and rilpivirine for the treatment of HIV.

David Rial-Crestelo, Adriana Pinto-Martínez, Federico Pulido

|Aug 09, 2019
Novel association of five HLA alleles with HIV-1 progression in Spanish long-term non progressor patients.

Eva Ramírez de Arellano, Francisco Díez-Fuertes, Francisco Aguilar

Pageof 1

Frequent Collaborators

2 joint publications

David Rial-Crestelo

1 joint publications

Eva Ramírez de Arellano

1 joint publications

Susana Sánchez-Lara

1 joint publications

Alfonso Cabello-Ubeda